On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

OncBioMune Pharmaceuticals, Inc. (OBMP) is “One to Watch”

Given the latest official data on prostate cancer prevalence compiled by the CDC and the GLOBOCAN project, over 1.1 million cases of what is the fourth most common cancer in both sexes combined and the second most common cancer in men, were reported back in 2012 alone. Prostate cancer accounts for roughly 15 percent of all cancers in men and is the fifth most lethal, with around 307,000 deaths in 2012. A continually rising rate of incidents are being reported in developed economies as prostate specific antigen (PSA) tests become more and more ubiquitous, giving investors a clear portrait of the demand landscape moving forward for therapeutics. Incident rates for prostate cancer will only rise in parallel (or greater) alongside overall cancer rates, for which the CDC estimates the figure will rise by 36.8 percent to 19.3 million new cases by 2025.

PSA tests have helped to rapidly differentiate prostate cancer from a common condition where the prostate enlarges on its own, which is almost inevitable in men as they age, known as benign prostatic hyperplasia (BPH). However, even with the emergence of five new drugs since 2010 from players like Dendreon (OTC: DNDNQ) and Medivation (NASDAQ: MDVN) working in partnership with Astellas (OTC: ALPMY), as well as heavy-hitters such as Sanofi (NYSE: SNY), Johnson & Johnson (NYSE: JNJ) and Bayer (OTC: BAYRY) – the space is still largely underserved, with extant indications only achieving marginal efficacy. Even the more ingenious indications, which utilize aspects of personalized medicine to program a specific patient’s immune system, have seen only partial completeness in achieving the desired endpoints.

If patients can be diagnosed early enough, localized prostate cancer is more easily treatable, but there is currently no curative option available for patients once the disease has progressed to the point of being classed as castration-resistant prostate cancer (CRPC). According to forecasts by energy and healthcare research group GlobalData, the number of late-stage pipeline agents that are commercially available will nearly double by 2023, with the vast majority aimed at CRPC, triggering a three-fold increase in the size of the therapy market across the nine major global economies. We are looking at a 12.4 percent CAGR from 2013 through 2023 according to GlobalData, when the therapeutics market will hit upwards of $8.3 billion, driven by the advent of new premium-priced therapies and label extensions of extant commercial indications. The robust pipeline for new therapies is particularly interesting as many of the developing candidates possess wholly unique mechanisms of action which set them apart from existing treatments, as well as the targeting of different proteins and pathways.

One of the most exciting developers in this game today is a clinical stage biopharma with truly innovative proprietary vaccine technology at their disposal, OncBioMune Pharmaceuticals (OTCQB: OBMP), which recently secured Notices of Allowance for patents on its leading prostate cancer vaccine candidate ProscaVax™ in both China and Ukraine. Already well-established via a phase 1/2 clinical trial in biopsy confirmed patients with elevated PSA, ProscaVax, which is designed to stimulate the host immune system into attacking the cancer without harming the patient, was administered in the phase 1/2 trail using a one-two punch protocol developed from insights and techniques employed in breast cancer vaccinations. Several weeks after an initial round containing a pre-tuned concentration of prostate specific antigen and biological adjuvant, serum PSA concentrations are again evaluated before a second course of shots are administered in combination with low dose IL-2 (a cytokine signaling molecule, interleukin 2) over a period of about six months.

The Chinese and Ukrainian Notices of Allowance add substantially to OBMP’s already solid IP position and protect the vaccine in those countries through 2031, reinforcing the earlier USPTO patent for ProscaVax, as well as the related Notice of Allowance for an additional patent application that was filed with the USPTO. Currently nearing completion of a fully funded phase 1 trial this month (in part paid for by the US Navy Cancer Vaccine Program) that is being conducted at UCSD Medical School under an IND from the FDA, ProscaVax is already slated to begin its key phase 2 clinical study early next year at Harvard Cancer Centers, and could rapidly become a leading therapeutic vaccine with serious profitability for OncBioMune once FDA approval has been granted.

Phase 1 trial data was recently offered in a poster presentation at the CRI-CIMT-EATI-AACR: Inaugural International Cancer Immunotherapy Conference in New York and the results offered in this poster presentation roundly supports the work OBMP has been doing, showing increased immunity to the PSA antigen after administration of the vaccine, as well as a delimiting of the PSA progression rate in those who had previously received standard therapies. With eight out of nine patients in the phase 1 trial showing increased immune response to PSA at (validated via lymphocyte blastogenesis assay) 31 weeks after the first vaccine and there being an unmistakably clear lack of toxicity as a result of ProscaVax being administered, OBMP is now well-equipped to receive FDA clearance for phase 2.

The company’s secondary candidate, OvcaVax, has similar potential in the $55.5 million global breast cancer therapeutics market, which is expected to hit upwards of $7.8 billion by 2023, growing at a CAGR of around 58.3 percent according to a recent report published by Transparency Market Research. OncBioMune actually has a much larger and equally compelling portfolio of targeted therapies under its belt as well, some of which are biosimilars to current blockbuster drugs. OvcaVax could put OBMP in direct competition with breast cancer therapeutic majors like Roche’s (OTC: RHHBY) Genentech, as well as Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), Novartis (NYSE: NVS), and AstraZeneca (NYSE: AZN).

In fact, OncBioMune actually obtained the first U.S. patent on a breast cancer vaccine back in 1994 and was also the first to employ GM-CSF and IL-2 cytokines as adjuvants. The company is currently heavily focused on tumor escape mechanisms in breast cancer via ongoing study of tumor stroma and the microenvironment, setting the company up for potential breakthroughs in specific adaptive immunotherapies, and OBMP already has some promising preliminary results in this area to boast of. The company’s recent ticker change and up-listing to OTCQB following the acquisition of Quint Media and approval by FINRA, as well as the tapping of former president and CEO of Entergy (NYSE: ETR) subsidiary Entergy New Orleans, Charles L. Rice, Jr. to its Board of Directors, shows just how serious a contender the company has now become. From both a clinical development and business model fundamentals standpoint OBMP (currently trading at $2.50 per share) is now starting to turn heads in the investment community as one of the most promising up-and-comer clinical-stage biopharmas available.

OncBioMune has an extremely promising immuno-oncology vaccine candidate in ProscaVax that is ready for phase 2 and which can directly address the unmet demand for a powerful prostate cancer therapeutic. The company has taken the proper steps to massively increase its market exposure and the commercial potential for OBMP’s broader pipeline is just starting to be understood by investors. OncBioMune has certainly become one to watch and interested parties should keep their ears to the ground for news about the upcoming phase 2 work on ProscaVax.

Take a closer look, visit http://oncbiomune.com/

Archives

Select A Month
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • May 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
  • June 2012
  • May 2012
  • April 2012
  • March 2012
  • February 2012
  • January 2012
  • December 2011
  • November 2011
  • October 2011
  • September 2011
  • August 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • January 2006
  • December 2005
  • October 2005
  • September 2005
  • Market Basics

    New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

    The Basics

    Newsletter Publishers

    Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

    Register

    Public Companies

    Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

    Get Covered